Erika Hamilton MD, FASCO
@erikahamilton9.bsky.social
Director of Breast Cancer Research Program at Sarah Cannon Research Institute | Wife | Mom to 2 Girls | Tweets are My Own #Oncology #BCSM, #Cancer.
Maple was very interested in the Derby 🐎
May 4, 2025 at 4:32 PM
Maple was very interested in the Derby 🐎
Look at what our practice did for us for Doctor's Day this year? Seriously so cute and thoughtful.
Definitely my best Doctor's Day ever! Thank you SCRI Oncology Partners!
Definitely my best Doctor's Day ever! Thank you SCRI Oncology Partners!
March 31, 2025 at 5:00 PM
Look at what our practice did for us for Doctor's Day this year? Seriously so cute and thoughtful.
Definitely my best Doctor's Day ever! Thank you SCRI Oncology Partners!
Definitely my best Doctor's Day ever! Thank you SCRI Oncology Partners!
#JSMO25 was amazing!
💪🏼 Had a fantastic session led by Makiko Ono on gender balance in oncology,
⭐️ a great joint @ascocancer.bsky.social / JSMO session on undruggable targets,
🌹 a beautiful Presidential Dinner....
🇯🇵 and got to squeeze in a visit to a shrine!
💪🏼 Had a fantastic session led by Makiko Ono on gender balance in oncology,
⭐️ a great joint @ascocancer.bsky.social / JSMO session on undruggable targets,
🌹 a beautiful Presidential Dinner....
🇯🇵 and got to squeeze in a visit to a shrine!
March 7, 2025 at 9:00 PM
#JSMO25 was amazing!
💪🏼 Had a fantastic session led by Makiko Ono on gender balance in oncology,
⭐️ a great joint @ascocancer.bsky.social / JSMO session on undruggable targets,
🌹 a beautiful Presidential Dinner....
🇯🇵 and got to squeeze in a visit to a shrine!
💪🏼 Had a fantastic session led by Makiko Ono on gender balance in oncology,
⭐️ a great joint @ascocancer.bsky.social / JSMO session on undruggable targets,
🌹 a beautiful Presidential Dinner....
🇯🇵 and got to squeeze in a visit to a shrine!
Asia Pacific Breast Cancer Symposium
February 22, 2025 at 11:02 PM
Asia Pacific Breast Cancer Symposium
Soooooo....I guess my addictive habit of buying cheap light-up seasonal decorations from Temu for less than $5 is drying up next week, huh?
Have to admit, I've been super pleasantly surprised by this stuff.
Have to admit, I've been super pleasantly surprised by this stuff.
February 2, 2025 at 6:43 PM
Soooooo....I guess my addictive habit of buying cheap light-up seasonal decorations from Temu for less than $5 is drying up next week, huh?
Have to admit, I've been super pleasantly surprised by this stuff.
Have to admit, I've been super pleasantly surprised by this stuff.
Why does coming in and seeing a new leaf on my office monastera make me irrationally happy?
#plants #simplejoys #makeagreatday
#plants #simplejoys #makeagreatday
January 7, 2025 at 4:59 PM
Why does coming in and seeing a new leaf on my office monastera make me irrationally happy?
#plants #simplejoys #makeagreatday
#plants #simplejoys #makeagreatday
Hello Mexico City! 🇲🇽
December 27, 2024 at 9:37 PM
Hello Mexico City! 🇲🇽
Merry Christmas to all!
We are ready here in Nashville- reindeer food has been spread and matching jammies are on.
Goodnight to everyone! Hope your holiday is filled with happiness, joy, and a touch of magic!
We are ready here in Nashville- reindeer food has been spread and matching jammies are on.
Goodnight to everyone! Hope your holiday is filled with happiness, joy, and a touch of magic!
December 25, 2024 at 12:44 AM
Merry Christmas to all!
We are ready here in Nashville- reindeer food has been spread and matching jammies are on.
Goodnight to everyone! Hope your holiday is filled with happiness, joy, and a touch of magic!
We are ready here in Nashville- reindeer food has been spread and matching jammies are on.
Goodnight to everyone! Hope your holiday is filled with happiness, joy, and a touch of magic!
December 18, 2024 at 12:21 PM
Fantastic ER+ #bcsm summary and algorithm by Dr. Danso at year in review.
First line CDK
2nd line profile driven
ADC/chemo once endo-R!
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
First line CDK
2nd line profile driven
ADC/chemo once endo-R!
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
December 13, 2024 at 11:06 PM
Fantastic ER+ #bcsm summary and algorithm by Dr. Danso at year in review.
First line CDK
2nd line profile driven
ADC/chemo once endo-R!
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
First line CDK
2nd line profile driven
ADC/chemo once endo-R!
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
Did anyone else buy Sally the Armadillo for their kids?
Raise 🖐️
Hard to make an armadillo look cute, but they nailed it.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Raise 🖐️
Hard to make an armadillo look cute, but they nailed it.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 13, 2024 at 8:43 PM
Did anyone else buy Sally the Armadillo for their kids?
Raise 🖐️
Hard to make an armadillo look cute, but they nailed it.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Raise 🖐️
Hard to make an armadillo look cute, but they nailed it.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Dr. Bianchini describes the 🐘 in the room at #SABCS24.
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 13, 2024 at 4:51 PM
Dr. Bianchini describes the 🐘 in the room at #SABCS24.
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Dr. Bianchini describes the 🐘 in the room at #SABCS24.
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 13, 2024 at 4:51 PM
Dr. Bianchini describes the 🐘 in the room at #SABCS24.
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
❓Are PD-L1 and PD1 not created equal in breast?
🔑It is clear, neoadjuvant compared to adj immunotherapy should be given
⚠️ highlights ER low should be included in ICI trials
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Dr. Chen shows that benefit of anthracycline is really beneficial for those with HIGH recurrence score (5% benefit)
Benefit primarily limited to tumors >2cm
Benefit in both pre and post meno
Alternative regimens not as good as T-AC
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Benefit primarily limited to tumors >2cm
Benefit in both pre and post meno
Alternative regimens not as good as T-AC
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 13, 2024 at 3:40 PM
Dr. Chen shows that benefit of anthracycline is really beneficial for those with HIGH recurrence score (5% benefit)
Benefit primarily limited to tumors >2cm
Benefit in both pre and post meno
Alternative regimens not as good as T-AC
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Benefit primarily limited to tumors >2cm
Benefit in both pre and post meno
Alternative regimens not as good as T-AC
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Dr. Krop emphasizes we don't have the data in #bcsm that the GI literature does for MRD.
🛑 Should NOT order tests (outside of a clinical trial) without clear actions to take based on results ‼️
❓Will outcomes be changed in ctDNA+? Unsure.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
🛑 Should NOT order tests (outside of a clinical trial) without clear actions to take based on results ‼️
❓Will outcomes be changed in ctDNA+? Unsure.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 13, 2024 at 3:31 PM
Dr. Krop emphasizes we don't have the data in #bcsm that the GI literature does for MRD.
🛑 Should NOT order tests (outside of a clinical trial) without clear actions to take based on results ‼️
❓Will outcomes be changed in ctDNA+? Unsure.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
🛑 Should NOT order tests (outside of a clinical trial) without clear actions to take based on results ‼️
❓Will outcomes be changed in ctDNA+? Unsure.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Dr. Turner presents #ZEST adj study of MRD in pts with HR + w/ BRCA & TNBC all comers w/ niraparib as intervention
147 had ctDNA+, only 40 randomized
Rad recurrence assoc w/ ⬆️ ctDNA level
RFI 5.4 -> 11.4 mo w/ niraparib
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
147 had ctDNA+, only 40 randomized
Rad recurrence assoc w/ ⬆️ ctDNA level
RFI 5.4 -> 11.4 mo w/ niraparib
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 13, 2024 at 3:12 PM
Dr. Turner presents #ZEST adj study of MRD in pts with HR + w/ BRCA & TNBC all comers w/ niraparib as intervention
147 had ctDNA+, only 40 randomized
Rad recurrence assoc w/ ⬆️ ctDNA level
RFI 5.4 -> 11.4 mo w/ niraparib
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
147 had ctDNA+, only 40 randomized
Rad recurrence assoc w/ ⬆️ ctDNA level
RFI 5.4 -> 11.4 mo w/ niraparib
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Dr. metzger presents #PATINA
Maint ET + HP +/- Palbo in 1st line ER+ and HER-2+ maint
📌29.1 vs. 44.3 mo PFS with Palbo w/ 52 mo f/u
OS not signif yet
Low counts, fatigue, and stomatitis AEs, discontinuations only 7% of pts though
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social #bcsm
Maint ET + HP +/- Palbo in 1st line ER+ and HER-2+ maint
📌29.1 vs. 44.3 mo PFS with Palbo w/ 52 mo f/u
OS not signif yet
Low counts, fatigue, and stomatitis AEs, discontinuations only 7% of pts though
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social #bcsm
December 12, 2024 at 5:58 PM
Dr. metzger presents #PATINA
Maint ET + HP +/- Palbo in 1st line ER+ and HER-2+ maint
📌29.1 vs. 44.3 mo PFS with Palbo w/ 52 mo f/u
OS not signif yet
Low counts, fatigue, and stomatitis AEs, discontinuations only 7% of pts though
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social #bcsm
Maint ET + HP +/- Palbo in 1st line ER+ and HER-2+ maint
📌29.1 vs. 44.3 mo PFS with Palbo w/ 52 mo f/u
OS not signif yet
Low counts, fatigue, and stomatitis AEs, discontinuations only 7% of pts though
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social #bcsm
It's a difficult topic to discuss- weight. Hugely personal, not easy to change, but impt.
4% ⬆️ recurrence in pts w/ node + #bcsm obese vs. lean
2% ⬆️ recurrence in pts with N0 dz
📌Magnitude of effect larger among premeno.
📌ER + AND ER neg
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
4% ⬆️ recurrence in pts w/ node + #bcsm obese vs. lean
2% ⬆️ recurrence in pts with N0 dz
📌Magnitude of effect larger among premeno.
📌ER + AND ER neg
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
December 12, 2024 at 5:15 PM
It's a difficult topic to discuss- weight. Hugely personal, not easy to change, but impt.
4% ⬆️ recurrence in pts w/ node + #bcsm obese vs. lean
2% ⬆️ recurrence in pts with N0 dz
📌Magnitude of effect larger among premeno.
📌ER + AND ER neg
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
4% ⬆️ recurrence in pts w/ node + #bcsm obese vs. lean
2% ⬆️ recurrence in pts with N0 dz
📌Magnitude of effect larger among premeno.
📌ER + AND ER neg
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
Prof. Kunkler presents SUPREMO - study of post mastectomy XRT in intermediate risk #bcsm
W/ 10 yrs f/u, 🚫diff in survival between XRT or not after mastectomy in those pts
Was numerically more local recurrences without radiation (2%)
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
W/ 10 yrs f/u, 🚫diff in survival between XRT or not after mastectomy in those pts
Was numerically more local recurrences without radiation (2%)
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
December 12, 2024 at 3:40 PM
Prof. Kunkler presents SUPREMO - study of post mastectomy XRT in intermediate risk #bcsm
W/ 10 yrs f/u, 🚫diff in survival between XRT or not after mastectomy in those pts
Was numerically more local recurrences without radiation (2%)
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
W/ 10 yrs f/u, 🚫diff in survival between XRT or not after mastectomy in those pts
Was numerically more local recurrences without radiation (2%)
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
@icromeattini.bsky.social presents EUROPA - ET alone or XRT alone in women >70 in luminal early #bcsm
XRT ☢️ affected QHS less than ET
@ 24 mo f/u, efficacy no diff
⬆️ AEs with ET
Big 🙋♀️: 2 yrs f/u not enough in ER+, later recurrences?
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
XRT ☢️ affected QHS less than ET
@ 24 mo f/u, efficacy no diff
⬆️ AEs with ET
Big 🙋♀️: 2 yrs f/u not enough in ER+, later recurrences?
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
December 12, 2024 at 3:11 PM
@icromeattini.bsky.social presents EUROPA - ET alone or XRT alone in women >70 in luminal early #bcsm
XRT ☢️ affected QHS less than ET
@ 24 mo f/u, efficacy no diff
⬆️ AEs with ET
Big 🙋♀️: 2 yrs f/u not enough in ER+, later recurrences?
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
XRT ☢️ affected QHS less than ET
@ 24 mo f/u, efficacy no diff
⬆️ AEs with ET
Big 🙋♀️: 2 yrs f/u not enough in ER+, later recurrences?
@sabcs.bsky.social
#SABCS24
@oncoalert.bsky.social
Dr. Garber presents OlympiA updated 10 yr data re: olaparib in adj #bcsm
Median f/u over 6 years now
iDFS 9.4% improved
BOTH HR+ and TNBC got benefit
DDFS 7.8% improved
OS improved by 4.4% w/ olaparib
#SABCS24
#bcsm
@sabcs.bsky.social
@oncoalert.bsky.social
Median f/u over 6 years now
iDFS 9.4% improved
BOTH HR+ and TNBC got benefit
DDFS 7.8% improved
OS improved by 4.4% w/ olaparib
#SABCS24
#bcsm
@sabcs.bsky.social
@oncoalert.bsky.social
December 11, 2024 at 5:24 PM
Dr. Garber presents OlympiA updated 10 yr data re: olaparib in adj #bcsm
Median f/u over 6 years now
iDFS 9.4% improved
BOTH HR+ and TNBC got benefit
DDFS 7.8% improved
OS improved by 4.4% w/ olaparib
#SABCS24
#bcsm
@sabcs.bsky.social
@oncoalert.bsky.social
Median f/u over 6 years now
iDFS 9.4% improved
BOTH HR+ and TNBC got benefit
DDFS 7.8% improved
OS improved by 4.4% w/ olaparib
#SABCS24
#bcsm
@sabcs.bsky.social
@oncoalert.bsky.social
Dr. Lambertini presents data around risk reducing surgery in young BRCA carriers with a PRIOR breast cancer
Both mastectomies and oophorectomy were associated with
⬆️ OS
⬆️ DFS
⬆️ BCFI
RRM irrespective of which BRCA gene alteration, RRSO benefit higher among BRCA1
#SABCS24
@sabcs.bsky.social
Both mastectomies and oophorectomy were associated with
⬆️ OS
⬆️ DFS
⬆️ BCFI
RRM irrespective of which BRCA gene alteration, RRSO benefit higher among BRCA1
#SABCS24
@sabcs.bsky.social
December 11, 2024 at 5:16 PM
Dr. Lambertini presents data around risk reducing surgery in young BRCA carriers with a PRIOR breast cancer
Both mastectomies and oophorectomy were associated with
⬆️ OS
⬆️ DFS
⬆️ BCFI
RRM irrespective of which BRCA gene alteration, RRSO benefit higher among BRCA1
#SABCS24
@sabcs.bsky.social
Both mastectomies and oophorectomy were associated with
⬆️ OS
⬆️ DFS
⬆️ BCFI
RRM irrespective of which BRCA gene alteration, RRSO benefit higher among BRCA1
#SABCS24
@sabcs.bsky.social
I'm really proud of that emoji combination too, btw
December 11, 2024 at 5:02 PM
I'm really proud of that emoji combination too, btw
Does remote symptom monitoring improve fatigue in MBC?
Maybe so. Likely prompts intervention and addressing symptoms sooner than waiting for next visits or having discussion skipped for other priorities in the exam room.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm
Maybe so. Likely prompts intervention and addressing symptoms sooner than waiting for next visits or having discussion skipped for other priorities in the exam room.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm
December 11, 2024 at 4:54 PM
Does remote symptom monitoring improve fatigue in MBC?
Maybe so. Likely prompts intervention and addressing symptoms sooner than waiting for next visits or having discussion skipped for other priorities in the exam room.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm
Maybe so. Likely prompts intervention and addressing symptoms sooner than waiting for next visits or having discussion skipped for other priorities in the exam room.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm